Intelligent Bio Solutions financials
$1.63−1.21%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 |
|---|---|---|---|---|
| Revenue | $4.2M | $3.1M | $3.1M | $1.3M |
| Gross profit | $2.0M | $1.2M | $1.4M | $326.7K |
| Gross margin | 48.6% | 40.8% | 45.8% | 26.0% |
| Operating income | -$12.6M | -$10.7M | -$10.3M | -$12.6M |
| Net income | -$12.4M | -$10.6M | -$10.2M | -$10.6M |
| Net margin | −294.9% | −346.2% | −326.4% | −845.9% |
| Diluted EPS | $-8.44 | $-20.04 | $-63.80 | $-1270.00 |
| EBITDA | -$11.1M | -$9.3M | -$9.3M | -$7.5M |
| Operating cash flow | -$11.9M | -$9.7M | -$9.6M | -$7.4M |
| Free cash flow | -$12.1M | -$9.9M | -$9.8M | -$7.9M |
| Diluted shares | 1.5M | 0.5M | 0.2M | 0.0M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|
| Cash & equivalents | $4.0M | $1.0M | $6.3M | $1.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $197.1K | $515.3K | $756.1K |
| Total assets | $11.9M | $8.2M | $13.8M | $10.4M |
| Total liabilities | $6.7M | $5.4M | $5.6M | $6.7M |
| Shareholders' equity | $5.3M | $2.8M | $8.2M | $3.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology